ACET Financials

Income Statement
MetricQ3 2026Q2 2026Q1 2026Q4 2025Q3 2025
Revenue
0
0
0
0
0
Cost of Revenue
0
0
0
0
0
Gross Profit
0
0
0
0
0
Operating Expenses
19.8M
-11.2%
22.3M
+3.4%
21.6M
-32.4%
31.9M
+14.1%
28.0M
R&D
15.6M
-15.3%
18.4M
+5.5%
17.5M
-30.2%
25.0M
+9.6%
22.9M
SG&A
4.2M
+8.3%
3.9M
-5.7%
4.1M
-40.4%
6.8M
+34.3%
5.1M
Operating Income
-19796000
+11.2%
-22301000
-3.4%
-21570000
+32.4%
-31886000
-14.1%
-27952000
EBITDA
-18757000
+11.1%
-21102000
-4.3%
-20228000
+33.5%
-30413000
-15.3%
-26379000
Net Income
-18878000
+11.6%
-21358000
-5.5%
-20244000
+33.7%
-30516000
-13.6%
-26856000
EPS (Basic)
$-1.76
+11.6%
$-1.99
-5.9%
$-1.88
+35.4%
$-2.91
+38.3%
$-4.72
EPS (Diluted)
$-1.76
+11.6%
$-1.99
-5.9%
$-1.88
+35.4%
$-2.91
+38.3%
$-4.72
Shares (Diluted)
10.7M
+0.0%
10.7M
+0.0%
10.7M
+2.4%
10.5M
+84.2%
5.7M
Adicet Bio (ACET) — Financials